Evidence map›Paper›PMID 40319142›Full record

ArticleOncogene2025

Single-cell chromosome and bulk transcriptome analysis as a diagnostic tool to differentiate between localized and metastatic pheochromocytoma and sympathetic paraganglioma.

Annika M A Berends, René Wardenaar, Hilda van den Bos, Andréa E Tijhuis, Thera P Links, Richard A Feelders, Leo J Hofland, Schelto Kruijff, Karel Pacak, Diana C J Spierings and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Annika M A Berends *Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. m.a.berends@umcg.nl.ORCID http://orcid.org/0000-0002-8440-332X
René Wardenaar *European Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-9891-1897
Hilda van den BosEuropean Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Andréa E TijhuisEuropean Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Thera P LinksDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Richard A FeeldersDepartment of Endocrinology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Leo J HoflandDepartment of Endocrinology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Schelto KruijffDepartment of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Karel PacakSection on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-3541-3767
Diana C J SpieringsEuropean Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0001-8403-474X
Michiel N KerstensDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Floris FoijerEuropean Research Institute for the Biology of Ageing, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.ORCID http://orcid.org/0000-0003-0989-3127

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately 10-20% of patients with pheochromocytoma or sympathetic paraganglioma (PPGL) develop metastatic disease, most often as metachronous lesions. Unfortunately, there is a lack of accurate biomarkers that can predict the biologic behavior of a PPGL at the initial diagnosis. We investigated tumor samples from patients with PPGL and a diagnosis of either localized or metastatic disease with synchronous or metachronous metastases and performed a comprehensive molecular analysis through application of single-cell whole-genome sequencing and bulk transcriptome analysis, including variant detection analysis of RNA sequences. We found that PPGL displayed complex karyotypes with recurrent aneuploidies and substantial cell-to-cell karyotype variability, indicating ongoing chromosomal instability (CIN) in both localized and metastatic tumors. Transcriptome analysis on the other hand revealed several differences between localized and metastatic PPGL including TNFα and TGFβ signaling in metastatic PPGL that were already detectable in primary tumor samples of initially non-metastatic-appearing PPGLs that developed metachronous metastases. Altogether our findings indicate that while localized and metastatic PPGL in general have comparable genomic landscapes, they do show transcriptional differences that are already detectable in primary tumor PPGL before development of metastases. This finding could provide an important tool for improvement of patient stratification at initial diagnosis.

Indexed as

Chromosomes, HumanParagangliomaPheochromocytomaSingle-Cell AnalysisTranscriptomeAdultAgedAneuploidyFemaleGene Expression Regulation, NeoplasticHumansKaryotypeMaleMiddle AgedNeoplasm MetastasisSignal Transduction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.